Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NIH to Fund Collaborations with Industry to Identify New Uses for Existing Compounds

Published: Wednesday, June 19, 2013
Last Updated: Wednesday, June 19, 2013
Bookmark and Share
Crowdsourcing initiative will enable exploration of potential treatments in eight disease areas.

The National Institutes of Health has awarded $12.7 million to match nine academic research groups with a selection of pharmaceutical industry compounds to explore new treatments for patients in eight disease areas, including Alzheimer’s disease, Duchenne muscular dystrophy and schizophrenia.

The collaborative pilot initiative, called Discovering New Therapeutic Uses for Existing Molecules, is led by the National Center for Advancing Translational Sciences (NCATS) and funded by the NIH Common Fund.

The process of developing a new therapeutic is long and difficult. The average length of time from target discovery to approval of a new drug is more than 13 years, and the failure rate exceeds 95 percent.

This failure rate means, however, that many existing partially developed compounds could be advanced to clinical trials more quickly than starting from scratch.

“With thousands of diseases remaining untreatable, there is a sense of urgency to accelerate the pace at which discoveries are transformed into therapies for patients,” said Health and Human Services Secretary Kathleen Sebelius.

Sebelius continued, “This program helps forge partnerships between the pharmaceutical industry and the biomedical research community to work together to tackle problems that are beyond the scope of any one organization or sector.”

“Innovative, collaborative approaches that improve the therapeutic pipeline are crucial for success,” said NIH Director Francis S. Collins, M.D., Ph.D. “This unique collaboration between academia and industry holds the promise of trimming years from the long and expensive process of drug development.”

AbbVie (formerly Abbott); AstraZeneca; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen Research & Development, LLC; Pfizer; and Sanofi are participating in the pilot phase of the program.

NCATS launched this initiative in 2012 to help re-engineer the research pipeline using an innovative strategy to identify new uses for compounds that have undergone significant research and development by industry, including safety testing in humans.

The center crowdsourced the industry compounds to academic researchers nationwide to gain ideas for new therapeutic uses with the ultimate goal of developing new treatments for patients.

The program also tested newly created template agreements, which enabled negotiations to be completed in fewer than 11 weeks, versus a typical timeline of a year or more.

“Public-private collaborations are crucial for successful translation; no one organization can succeed alone,” said NCATS Director Christopher P. Austin, M.D. “This initiative has created a marketplace to connect academic researchers with potential new drugs, as well as template agreements that streamline the process by limiting the amount of negotiation required before a project can begin.”

Each award recipient will test a selected compound for its effectiveness against a previously unexplored disease or condition. The eight disease areas represented are alcohol dependence, Alzheimer’s disease, calcific aortic valve stenosis (a condition in which the heart valve hardens and makes it difficult to pump blood out of the heart), nicotine dependence, peripheral artery disease, schizophrenia and two rare diseases: Duchenne muscular dystrophy and the progressive lung disease lymphangioleiomyomatosis.

For more details about each project, please visit http://www.ncats.nih.gov/therapeutics-projects.html. The projects, award recipient principal investigators and industry partners are:

The efficacy and safety of a selective estrogen receptor beta agonist (LY500307)
Academic Partner: Alan Breier, M.D., Indiana University, Indianapolis
Industry Partner: Eli Lilly and Company

Fyn inhibition by AZD0530 for Alzheimer’s disease
Academic Partners: Stephen M. Strittmatter, M.D., Ph.D.; Haakon Berge Nygaard, M.D., Ph.D.; and Christopher H. Van Dyck, M.D., Yale University, New Haven, Conn.
Industry Partner: AstraZeneca

Medication development of a novel therapeutic for smoking cessation
Academic Partners: Darlene H. Brunzell, Ph.D., Virginia Commonwealth University, Richmond and Kenneth Alan Perkins, Ph.D., University of Pittsburgh
Industry Partner: Janssen Research & Development, LLC

A novel compound for alcoholism treatment: A translational strategy
Academic Partner: Fatemeh Akhlaghi, Pharm.D., Ph.D., University of Rhode Island, Kingston
NIH Intramural Partner: Lorenzo Leggio, M.D., Ph.D., M.Sc., National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse
Industry Partner: Pfizer

Partnering to treat an orphan disease: Duchenne muscular dystrophy
Academic Partners: Kathryn R. Wagner, M.D., Ph.D., Kennedy Krieger Institute, Baltimore
and Stanley C. Froehner, Ph.D., University of Washington, Seattle
Industry Partner: Sanofi

Reuse of ZD4054 for patients with symptomatic peripheral artery disease (PAD)
Academic Partner: Brian H. Annex, M.D., University of Virginia, Charlottesville
Industry Partner: AstraZeneca

Therapeutic strategy for lymphangioleiomyomatosis (LAM)
Academic Partner: N. Tony Eissa, M.D., Baylor College of Medicine, Houston
Industry Partner: AstraZeneca

Therapeutic strategy to slow progression of calcific aortic valve stenosis
Academic Partners: Jordan D. Miller, Ph.D.; Maurice Enriquez-Sarano, M.D.; and
Hartzell V. Schaff, M.D., Mayo Clinic, Rochester, Minn.
Industry Partner: Sanofi

Translational neuroscience optimization of GlyT1 inhibitor for cognitive impairments associated with schizophrenia
Academic Partner: John H. Krystal, M.D., Yale University, New Haven, Conn.
Industry Partner: Pfizer

These cooperative agreements will fund projects for researchers to conduct pre-clinical validation and additional safety studies as needed. If specific milestones are met, clinical feasibility studies or proof-of-concept clinical trials will be initiated to test whether the selected compounds may be effective as treatments for other diseases. The projects will be supported for up to three years.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Vital Protein in Healthy Fertilization Process Identified
Researchers at the National Institutes of Health have discovered a protein that plays a vital role in healthy egg-sperm union in mice.
Monday, July 27, 2015
NIH Joins Public-Private Partnership to Fund Research on Autism Biomarkers
Biomarkers Consortium project to improve tools for measuring and treating social impairment in children with autism.
Tuesday, July 21, 2015
Mystery of the Tubulin Code Unravelled
NIH study provides a glimpse into the code that controls variety of cell functions.
Wednesday, May 13, 2015
Mouse Study Reveals Potential Clue to Extra Fingers or Toes
NIH-funded study finds that gene appears to regulate protein signals inside the cell.
Tuesday, December 02, 2014
NIH Grant for Texas Biomed to Perform Mass Spec-Based Studies into Heart Disease
Institute awarded $2.7M grant from the NIH to fund innovative approaches to genetics research for the development of new therapies for heart disease and other conditions.
Wednesday, August 20, 2014
GTEx Project to Expand Functional Studies of Genomic Variation
Larger set of human tissues to be analyzed to contribute to a database and tissue bank that researchers can use to study how genomic variants influence gene activity.
Wednesday, August 06, 2014
Subcellular Imaging Visualizes Structures of Brain Receptors
The advance opens a new window to study protein interactions in cell membranes in exquisite detail.
Tuesday, August 05, 2014
NIH Funds $24M into Alzheimer’s Disease Genome Research
Scientists will analyze genome sequence data to identify gene risk, protective factors.
Tuesday, July 08, 2014
Muscle Weakness Seen in Alcoholism Linked to Mitochondrial Repair Issues
Scientists found evidence that chronic heavy alcohol use affects a gene involved in mitochondrial repair and muscle regeneration.
Tuesday, April 22, 2014
Gene Linked to Excess Male Hormones in Female Infertility Disorder
Discovery by NIH-supported researchers may lead to diagnostic test, treatment.
Thursday, April 17, 2014
Unexpected Protein Partnership has Implications for Cancer Treatment
Scientists have identified a macrophage that works together in response to cancer drugs to increase inflammation in a way that may alter tumor growth.
Tuesday, April 15, 2014
Too Much Protein May Kill Brain Cells As Parkinson’s Progresses
NIH-funded study on key Parkinson’s gene finds a possible new target for monitoring the disease.
Friday, April 11, 2014
Underlying Genetics and Marker For Stroke Discovered
NIH-funded findings point to new potential strategies for disease prevention, treatment.
Friday, March 21, 2014
Speeding Validation of Disease Targets
NIH, industry and non-profits join forces to develop new treatments earlier, beginning with Alzheimer’s, type 2 diabetes, and autoimmune disorders.
Tuesday, February 04, 2014
Study Breaks Blood-Brain Barriers to Understanding Alzheimer’s
NIH-funded study suggests brain blood vessel cells may be therapeutic targets for Alzheimer’s disease.
Friday, December 13, 2013
Scientific News
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Rice Disease-Resistance Discovery Closes the Loop for Scientific Integrity
Researchers reveal how disease resistant rice detects and responds to bacterial infections.
The Mystery of the Instant Noodle Chromosomes
Researchers from the Lomonosov Moscow State University evaluated the benefits of placing the DNA on the principle of spaghetti.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!